» Articles » PMID: 32988401

Single-cell Transcriptome Analysis of Tumor and Stromal Compartments of Pancreatic Ductal Adenocarcinoma Primary Tumors and Metastatic Lesions

Overview
Journal Genome Med
Publisher Biomed Central
Specialty Genetics
Date 2020 Sep 29
PMID 32988401
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Solid tumors such as pancreatic ductal adenocarcinoma (PDAC) comprise not just tumor cells but also a microenvironment with which the tumor cells constantly interact. Detailed characterization of the cellular composition of the tumor microenvironment is critical to the understanding of the disease and treatment of the patient. Single-cell transcriptomics has been used to study the cellular composition of different solid tumor types including PDAC. However, almost all of those studies used primary tumor tissues.

Methods: In this study, we employed a single-cell RNA sequencing technology to profile the transcriptomes of individual cells from dissociated primary tumors or metastatic biopsies obtained from patients with PDAC. Unsupervised clustering analysis as well as a new supervised classification algorithm, SuperCT, was used to identify the different cell types within the tumor tissues. The expression signatures of the different cell types were then compared between primary tumors and metastatic biopsies. The expressions of the cell type-specific signature genes were also correlated with patient survival using public datasets.

Results: Our single-cell RNA sequencing analysis revealed distinct cell types in primary and metastatic PDAC tissues including tumor cells, endothelial cells, cancer-associated fibroblasts (CAFs), and immune cells. The cancer cells showed high inter-patient heterogeneity, whereas the stromal cells were more homogenous across patients. Immune infiltration varies significantly from patient to patient with majority of the immune cells being macrophages and exhausted lymphocytes. We found that the tumor cellular composition was an important factor in defining the PDAC subtypes. Furthermore, the expression levels of cell type-specific markers for EMT cancer cells, activated CAFs, and endothelial cells significantly associated with patient survival.

Conclusions: Taken together, our work identifies significant heterogeneity in cellular compositions of PDAC tumors and between primary tumors and metastatic lesions. Furthermore, the cellular composition was an important factor in defining PDAC subtypes and significantly correlated with patient outcome. These findings provide valuable insights on the PDAC microenvironment and could potentially inform the management of PDAC patients.

Citing Articles

Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes.

Zhang X, Lan R, Liu Y, Pillarisetty V, Li D, Zhao C NPJ Precis Oncol. 2025; 9(1):58.

PMID: 40032924 PMC: 11876354. DOI: 10.1038/s41698-025-00848-2.


c-Rel drives pancreatic cancer metastasis through Fibronectin-Integrin signaling-induced isolation stress resistance and EMT activation.

Bakirdogen D, Gorgulu K, Xin J, Alcala S, Ruiz-Canas L, Frank K bioRxiv. 2025; .

PMID: 39975057 PMC: 11838362. DOI: 10.1101/2025.01.29.635445.


Promotion Mechanisms of Stromal Cell-Mediated Lung Cancer Development Within Tumor Microenvironment.

Wu S, Hu Y, Sui B Cancer Manag Res. 2025; 17:249-266.

PMID: 39957904 PMC: 11829646. DOI: 10.2147/CMAR.S505549.


Single-cell atlas of human pancreatic islet and acinar endothelial cells in health and diabetes.

Craig-Schapiro R, Li G, Chen K, Gomez-Salinero J, Nachman R, Kopacz A Nat Commun. 2025; 16(1):1338.

PMID: 39915484 PMC: 11802906. DOI: 10.1038/s41467-024-55415-3.


Immune regulatory genes impact the hot/cold tumor microenvironment, affecting cancer treatment and patient outcomes.

Sang M, Ge J, Ge J, Tang G, Wang Q, Wu J Front Immunol. 2025; 15:1382842.

PMID: 39911580 PMC: 11794490. DOI: 10.3389/fimmu.2024.1382842.


References
1.
Hosein A, Huang H, Wang Z, Parmar K, Du W, Huang J . Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight. 2019; 5. PMC: 6777805. DOI: 10.1172/jci.insight.129212. View

2.
Steeg P . Targeting metastasis. Nat Rev Cancer. 2016; 16(4):201-18. PMC: 7055530. DOI: 10.1038/nrc.2016.25. View

3.
Bailey P, Chang D, Nones K, Johns A, Patch A, Gingras M . Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52. DOI: 10.1038/nature16965. View

4.
Brown J, Recht L, Strober S . The Promise of Targeting Macrophages in Cancer Therapy. Clin Cancer Res. 2017; 23(13):3241-3250. PMC: 5529121. DOI: 10.1158/1078-0432.CCR-16-3122. View

5.
Hingorani S, Zheng L, Bullock A, Seery T, Harris W, Sigal D . HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2017; 36(4):359-366. DOI: 10.1200/JCO.2017.74.9564. View